Michael O Koch, MD
Disclosures: Nothing to disclose
OMB No. 0925-0046, Biographical Sketch Format Page

OMB No. 0925-0001 and 0925-0002 (Rev. 10/15 Approved Through 10/31/2018)

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. DO NOT EXCEED FIVE PAGES.

NAME: Michael Koch

eRA COMMONS USER NAME (credential, e.g., agency login): RPILI1

POSITION TITLE: Professor of Urology, Chair of Urology

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

INSTITUTION AND LOCATION

DEGREE

(if applicable)

 

Completion Date

MM/YYYY

 

FIELD OF STUDY

 

Dartmouth College

Residency, Dartmouth College

Research fellowship

Urology Residency, Vanderbilt University

M.D.

Residency

None

Residency

1981

1981-1983

1983-1984

1984-1987

Medicine

Surgery

Physiology

Urology

 

A. Personal Statement

I started my professional career at Vanderbilt University in 1987 and had a funded laboratory effort in bladder cancer reconstruction for many years. I have been the chair of Urology and a professor of urology at Indiana University School of Medicine since 1998 where I have focused my clinical responsibilities on bladder and prostate cancer while also working on the administrative roles of building a world class urology department with a translational research program. We were successful several years ago in recruiting Roberto Pili to co-lead our effort in GU cancer along with myself and since that time we have worked closely together to develop a joint clinical and research program. In the past several years we have amassed an extremely large tissue biobank, we have extensive basic science research collaborations with Purdue University, and we have a combined clinical research program. My own research focus has been on the development of focal therapy strategies in prostate cancer, novel approaches to the management of metastatic prostate cancer, biomarkers in prostate cancer, and variant histology’s in bladder cancer. As the director of the urology clinics across the IU Health system and as a clinician that dedicates his practice to prostate and cancer, I can facilitate enrollment in clinical trials.

 

B. Positions and Honors

Professional Experience 

1987 - 1991                             Assistant Professor

Department of Urology

Vanderbilt University School of Medicine

Nashville, Tennessee

1991 - 1992                            Interim Chairman

Department of Urology

Vanderbilt University School of Medicine

Nashville, Tennessee

1992 - 1998                            Associate Professor

Department of Urologic Surgery

Vanderbilt University School of Medicine

Nashville, Tennessee

1995 - 1998                             Vice Chairman

Department of Urologic Surgery

Vanderbilt University School of Medicine

Nashville, Tennessee

1998 - Present                             Professor and Chairman

Department of Urology

Indiana University School of Medicine

Indianapolis, Indiana

 

Honors and Awards

Distinction in Engineering Major, Dartmouth College, 1977

Cum Laude, Dartmouth College, 1977

Alpha Omega Alpha Honor Medical Society, Dartmouth Medical School, 1981

Honorable Mention, American Urological Association Sponsored Essay Contest in Laboratory Research, 1985

Member of European Association of Urology - American Urological Association Exchange Program, 1996

Elected to American Association of Genitourinary Surgeons, 2004 (75 US members)

Named the John P. Donohue Professor of Urology, 2008

Elected to the Clinical Society of Genitourinary Surgeons, 2009 (25 US members)

Distinguished Contribution Award, 2015 American Urologic Association

 

 

 

C. Contribution to Science

              I have 183 publications in peer reviewed journals. Selected recent and relevant research publications are listed below.

 

I would respectfully submit that I have made significant contribution in four specific areas.

 

  1. Early on in my career I devoted a significant amount of time and had funded basic science research studying the metabolic consequences of complex urinary reconstruction after cystectomy. I have promoted innovative reconstructive techniques and written about the long-term results with these techniques with respect to both complications and quality of life outcomes.[1],[2],[3],[4],[5]

 

  1. I was the first in the US to author and conduct trial on the use of focused ultrasound ablation of the prostate to treat prostate cancer. Initially we conducted a trial using whole gland ablation but now with advances in PSMA based and MRI fusion technology we are pursuing trials in partial gland ablation. We were recently the lead US trial in transurethral ultrasound ablation for whole gland ablation under MRI guidance.[6]

 

  1. We were the first to report a large series of plasmacytoid and other variants in urothelial cancer and to demonstrate the unusual growth patterns and chemotherapeutic resistance in this disease.[7],[8],[9],[10],[11]
  2. We have consistently reported on the refining of surgical techniques to facilitate and demonstrate the limitations of surgical management of high-risk prostate cancer[12],[13],[14],[15],[16],[17],[18]

 

 

 


 

 

 

 

D. Research Support

Ongoing Research Support

 

              None currently

 

Completed Research Support (selected)

 

1988 - 1990               Veterans Administration Research Advisory Group, Metabolic Complications of Urinary Diversion Through Intestinal Segments, $60,500

 

1990 - 1993               Department of Veterans Affairs Medical Center, Merit Review Grant, Pathophysiology of Metabolic Alterations Following Urinary Diversion, $128,800

 

1993 - 1996               Department of Veterans Affairs Medical Center, Merit Review Grant, Mechanisms of Potassium and Ammonium Absorption in Intestine, $158,100.

 

1997                                                                       Gene Therapy Pilot Project, $35,000.

 

1997 - 1998               National Cancer Institute Cancer Center Support Grant, Progression of prostate cancer to androgen independence: a role for the androgen receptor, $15,000.

 

2001 - 2010               Selenium and Vitamin E Cancer Prevention trial (SWOG), $2,500,000/12 years-Principal investigator

 


[1] Metabolic and Nutritional Consequences of Urinary Diversion Using Intestinal Segments to Reconstruct the Urinary Tract.

Roth JD, Koch MO.

Urol Clin North Am. 2018 Feb;45(1):19-24. doi: 10.1016/j.ucl.2017.09.007. Review.

 

[2] Short-term morbidity and mortality of Indiana pouch, ileal conduit, and neobladder urinary diversion following radical cystectomy.

Monn MF, Kaimakliotis HZ, Cary KC, Pedrosa JA, Flack CK, Koch MO, Bihrle R.

Urol Oncol. 2014 Nov;32(8):1151-7. doi: 10.1016/j.urolonc.2014.04.009. Epub 2014 May 23.

 

[3] Mechanism of ammonium transport by intestinal segments following urinary diversion: evidence for ionized NH4+ transport via K(+)-pathways.

Hall MC, Koch MO, McDougal WS.

 

[4] Urinary solute transport by intestinal segments: a comparative study of ileum and colon in rats.

Koch MO, Gurevitch E, Hill DE, McDougal WS.

 

[5] Long-term Health-related Quality of Life Outcomes Following Radical Cystectomy.

Gellhaus PT, Cary C, Kaimakliotis HZ, Johnson CS, Weiner M, Koch MO, Bihrle R.

Urology. 2017 Aug;106:82-86. doi: 10.1016/j.urology.2017.03.053.

 

[6] Phase I/II trial of high intensity focused ultrasound for the treatment of previously untreated localized prostate cancer.

Koch MO, Gardner T, Cheng L, Fedewa RJ, Seip R, Sanghvi NT.

J Urol. 2007 Dec;178(6):2366-70; discussion 2370-1. Epub 2007 Oct 22. Erratum in: J Urol. 2008 Jan;179(1):386. Sangvhi, Narendra T [corrected to Sanghvi, Narendra T]

 

[7] Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology.

Kaimakliotis HZ, Monn MF, Cho JS, Pedrosa JA, Hahn NM, Albany C, Gellhaus PT, Cary KC, Masterson TA, Foster RS, Bihrle R, Cheng L, Koch MO.

Future Oncol. 2016 Aug;12(15):1795-804. doi: 10.2217/fon-2016-0056. Epub 2016 Jun 3.

 

[8] Contemporary bladder cancer: variant histology may be a significant driver of disease.

Monn MF, Kaimakliotis HZ, Pedrosa JA, Cary KC, Bihrle R, Cheng L, Koch MO.

Urol Oncol. 2015 Jan;33(1):18.e15-18.e20. doi: 10.1016/j.urolonc.2014.10.001. Epub 2014 Nov 1.

 

[9] Lymph node metastases in patients with urothelial carcinoma variants: influence of the specific variant on nodal histology.

Rice KR, Koch MO, Kao CS, Pedrosa JA, Kaimakliotis HZ, Masterson TA, Bihrle R, Cheng L.

Urol Oncol. 2015 Jan;33(1):20.e23-20.e29. doi: 10.1016/j.urolonc.2014.06.012. Epub 2014 Jul 18.

 

[10] Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm?

Kaimakliotis HZ, Monn MF, Cary KC, Pedrosa JA, Rice K, Masterson TA, Gardner TA, Hahn NM, Foster RS, Bihrle R, Cheng L, Koch MO.

 

[11] Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes.

Kaimakliotis HZ, Monn MF, Cheng L, Masterson TA, Cary KC, Pedrosa JA, Foster RS, Koch MO, Bihrle R.

Urology. 2014 May;83(5):1112-6. doi: 10.1016/j.urology.2013.12.035. Epub 2014 Feb 26

 

[12] A Parallel Randomized Clinical Trial Examining the Return of Urinary Continence after Robot-Assisted Radical Prostatectomy with or without a Small Intestinal Submucosa Bladder Neck Sling.

Bahler CD, Sundaram CP, Kella N, Lucas SM, Boger MA, Gardner TA, Koch MO.

J Urol. 2016 Jul;196(1):179-84. doi: 10.1016/j.juro.2016.01.010. Epub 2016 Jan 16.

 

[13] Oncologic and quality-of-life outcomes with wide resection in robot-assisted laparoscopic radical prostatectomy.

Yang DY, Monn MF, Kaimakliotis HZ, Cary KC, Cheng L, Koch MO.

Urol Oncol. 2015 Feb;33(2):70.e9-14. doi: 10.1016/j.urolonc.2014.07.003. Epub 2014 Sep 16.

 

[14] Open vs. robotic-assisted radical prostatectomy: a single surgeon and pathologist comparison of pathologic and oncologic outcomes.

Masterson TA, Cheng L, Boris RS, Koch MO.

Urol Oncol. 2013 Oct;31(7):1043-8. doi: 10.1016/j.urolonc.2011.12.002. Epub 2012 Jan 4.

 

[15] Radical prostatectomy as initial monotherapy for patients with pathologically confirmed high-grade prostate cancer.

Bahler CD, Foster RS, Bihrle R, Beck SD, Gardner TA, Sundaram CP, Masterson TA, Cheng L, Koch MO.

 

[16] Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy.

Cheng L, Davidson DD, Lin H, Koch MO.

Cancer. 2007 Nov 1;110(9):1967-72.

 

[17] Does wide primary perirectal dissection during radical retropubic prostatectomy alter pathologic and biochemical outcomes?

Dussinger AM, Beck SD, Cheng L, Koch MO.

Urology. 2005 Nov;66(5 Suppl):95-100.

 

[18] Biochemical disease-free survival in patients with a high prostate-specific antigen level (20-100 ng/mL) and clinically localized prostate cancer after radical prostatectomy.

Brandli DW, Koch MO, Foster RS, Bihrle R, Gardner TA.

BJU Int. 2003 Jul;92(1):19-22; discussion 22-3.